EssilorLuxottica downgraded at UBS on valuation, near-term risks By Investing.com
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2024
0mins
Source: Investing.com
UBS Downgrade: UBS has downgraded EssilorLuxottica shares to Neutral from Buy, citing near-term risks such as potential US tariffs and changes in consumer spending, despite a positive long-term outlook and strong stock performance in 2024.
Growth Forecasts and Risks: UBS anticipates a 6.3% growth for EssilorLuxottica in 2025, driven by innovation and M&A, while highlighting risks including US tariff impacts, FDA approval delays, and currency fluctuations; the price target is set at €248, indicating a 9% upside.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
